ZyVersa Therapeutics annual return on equity
2022
2022
2023
2024
ZyVersa Therapeutics Return on Equity (ROE) Growth & History (ZVSA)
ZyVersa Therapeutics's return on equity was −96.10% for fiscal 2024.
View full ZyVersa Therapeutics company overviewZyVersa Therapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2024 | 2024-12-31 | −96.10% | +81.43 pp |
| 2023 | 2023-12-31 | −177.53% | — |
| 2022 | 2022-12-31 | −14.09% | — |
| 2022 | 2022-12-12 | −28.84% | — |
ZyVersa Therapeutics quarterly return on equity
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2025 | 2025-06-30 | −31.08% | −3.22 pp |
| Q1 2025 | 2025-03-31 | −27.12% | −1.76 pp |
| Q4 2024 | 2024-12-31 | −18.29% | +68.38 pp |
| Q3 2024 | 2024-09-30 | −30.69% | −16.09 pp |
| Q2 2024 | 2024-06-30 | −27.86% | +106.17 pp |
| Q1 2024 | 2024-03-31 | −25.35% | −21.75 pp |
| Q4 2023 | 2023-12-31 | −86.67% | −61.02 pp |
| Q3 2023 | 2023-09-30 | −14.60% | — |
| Q2 2023 | 2023-06-30 | −134.03% | — |
| Q1 2023 | 2023-03-31 | −3.60% | — |
| Q4 2022 | 2022-12-12 | −25.66% | — |
ZyVersa Therapeutics return on equity trends
Between the periods ended 2022-12-12 and 2024-12-31, ZyVersa Therapeutics's return on equity decreased from −28.84% to −96.10%, a change of −67.26 percentage points. The latest reported quarter, Q2 2025, shows −31.08%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review ZyVersa Therapeutics source filings ↗